A 24-week, Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin, With or Without Metformin, in Patients With Type 2 Diabetes Mellitus.
Phase of Trial: Phase III
Latest Information Update: 28 Feb 2017
At a glance
- Drugs Vildagliptin (Primary) ; Insulin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharma A.G.
- 07 Jun 2017 Biomarkers information updated
- 01 Mar 2013 Results published in Diabetes, Obesity and Metabolism.
- 05 Oct 2012 Results presented at the 48th Annual Meeting of the European Association for the Study of Diabetes.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History